A number of research firms have changed their ratings and price targets for Quoin Pharmaceuticals (NASDAQ: QNRX):
- 10/19/2026 – Quoin Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $18.00 price target on the stock.
- 10/17/2026 – Quoin Pharmaceuticals was upgraded by Wall Street Zen to “sell”.
- 10/16/2026 – Quoin Pharmaceuticals had its “sell (e+)” rating reaffirmed by Weiss Ratings.
- 10/12/2026 – Quoin Pharmaceuticals is now covered by BTIG Research. They set a “buy” rating and a $14.00 price target on the stock.
- 10/12/2026 – Quoin Pharmaceuticals is now covered by BTIG Research. They set a “buy” rating and a $14.00 price target on the stock.
- 9/23/2026 – Quoin Pharmaceuticals is now covered by Lake Street Capital. They set a “buy” rating and a $20.00 price target on the stock.
Insider Buying and Selling at Quoin Pharmaceuticals
In other news, COO Denise P. Carter purchased 20,490 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was purchased at an average cost of $4.88 per share, with a total value of $99,991.20. Following the purchase, the chief operating officer owned 37,709 shares in the company, valued at approximately $184,019.92. This trade represents a 119.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Myers purchased 20,490 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The shares were purchased at an average cost of $4.88 per share, with a total value of $99,991.20. Following the completion of the purchase, the chief executive officer owned 37,713 shares in the company, valued at $184,039.44. This trade represents a 118.97% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 57,370 shares of company stock worth $279,966 over the last three months. 7.54% of the stock is owned by company insiders.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare diseases with significant unmet medical needs. The company’s programs are primarily designed to address disorders affecting the skin and other tissues, with an emphasis on topical drug-delivery technologies.
Quoin’s lead product candidate, QRX003, is an investigational topical lotion being developed for Netherton syndrome, a rare genetic skin disorder associated with impaired skin barrier function and inflammation.
Read More
- Five stocks we like better than Quoin Pharmaceuticals
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Quoin Pharmaceuticals Ltd Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals Ltd Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
